Impact__O on__O Commerce__B-PER Peppiatt-Wildman__I-PER and__O Wildman's__B-LOC unique__O approaches__O to__O investigate__O kidney__O and__O bladder__O function__O in__O a__O range__O of__O experimental__O models,__O including__O tissue__O slices,__O isolated__O and__O perfused__O organs,__O and__O urine__O have__O received__O substantial__O industrial__O financial__O support__O and__O so__O this__O research__O has__O had__O demonstrable__O impact__O on__O commerce.__O
Initial__O research__O using__O the__O novel__O kidney-slice__O methodology__O was__O presented__O in__O an__O `invited__O speaker'__O acute__O kidney__O injury__O session__O at__O the__O American__B-ORG Society__I-ORG of__I-ORG Nephrology__I-ORG `Renal__I-ORG Week'__I-ORG meeting__O in__O 2011,__O a__O meeting__O which__O attracts__O ~13,000__O international__O clinicians__O and__O researchers.__O
This__O presentation__O resulted,__O subsequently,__O in__O collaborative__O links__O being__O initiated__O with__O Pfizer__B-PER USA__I-PER and__O a__O collaborative__O research__O contract__O based__O on__O the__O application__O of__O the__O model__O to__O better__O understand__O acute__O kidney__O injury__O (AKI)__B-ORG is__O now__O in__O place__O at__O MSOP__B-ORG (Pfizer__I-ORG contract__O worth__O &#163;528K,__B-ORG 5.1).__O
Research__O at__O Pfizer__B-LOC has__O been__O directly__O influenced,__O therefore,__O by__O the__O possibilities__O opened__O up__O through__O use__O of__O this__O novel__O model__O and__O Pfizer__B-ORG have__O invested__O in__O this__O now__O because__O of__O its__O immediate__O potential__O for__O discovering__O new__O lead__O compounds__O for__O kidney__O disease__O (5.2).__O
In__O 2012,__O collaborative__O links__O were__O initiated__O with__O Biogen__B-ORG Idec__B-PER (USA)__I-PER and__O a__O pilot__O project,__O supported__O and__O funded__O by__O Biogen__B-ORG Idec__I-ORG (5.3),__O to__O investigate__O novel__O therapies__O in__O AKI__B-ORG is__O now__O underway__O to__O provide__O preliminary__O data__O for__O an__O MRC__B-ORG MICA__I-ORG application.__O
The__O direction__O of__O Biogen__B-ORG Idec's__I-ORG research__O programme__O has,__O therefore,__O been__O directly__O influenced__O by__O the__O research__O collaboration__O with__O Peppiatt-Wildman__B-ORG and__O Wildman__B-LOC (5.4).__O
Thus__O the__O focus__O and__O direction__O of__O research__O in__O two__O separate__O pharmaceutical__O companies__O has__O been__O directly__O influenced__O by__O the__O research__O of__O Peppiatt-Wildman__B-ORG and__I-ORG Wildman__I-ORG and__O these__O companies__O have__O invested__O in__O research__O and__O development__O as__O a__O direct__O result__O of__O this__O work.__O
This__O emphasises__O the__O requirement__O for__O Pharmaceutical__B-ORG companies__O to__O engage__O with__O Peppiatt-Wildman__B-ORG and__O Wildman__B-ORG in__O order__O to__O develop__O this__O model__O for__O their__O own__O internal__O use.__O
In__O the__O longer__O term,__O it__O is__O envisaged__O by__O both__O MSOP__B-ORG and__O industry__O that__O the__O impact__O of__O these__O two__O industry__O collaborations__O will__O be__O identification__O of__O novel__O therapeutics__O for__O AKI.__B-ORG
Impact__O on__O Clinical__O Practice__O The__O novel__O approaches__O developed__O have__O also__O made__O an__O impact__O on__O clinical__O practice.__O
Peppiatt-Wildman__O and__O Wildman__B-ORG initiated__O collaborative__O links__O with__O the__O Centre__B-ORG for__I-ORG Nephrology__I-ORG at__I-ORG UCL__I-ORG in__O order__O to__O identify__O how__O this__O novel__O model__O and__O methodology__O might__O be__O applied__O to__O address__O specific__O clinical__O problems.__O
Their__O methodology__O was__O used__O to__O address__O a__O highlighted__O clinical__O problem__O of__O drug-induced__O nephrotoxicity__O that__O was__O observed__O in__O a__O wide__O cross__O section__O of__O patients__O exposed__O to__O non-steroidal__O anti-inflammatory__O drugs__O and__O also__O in__O HIV__B-MISC patients__O being__O treated__O with__O anti-retrovirals.__O
This__O pioneering__O research__O not__O only__O addresses__O a__O costly__O clinical__O problem__O but__O also__O demonstrates__O how__O this__O model__O can__O be__O used__O to__O characterise__O other__O known__O cases__O of__O drug-induced__O nephrotoxicity.__O
Both__O Peppiatt-Wildman__B-MISC and__O Wildman__B-MISC hold__O Honorary__B-ORG positions__O in__O the__O Division__B-ORG of__I-ORG Medicine__I-ORG at__I-ORG UCL__I-ORG and__O provide__O lectures__O to__O renal__O clinicians,__O including__O the__O Renal__B-ORG Physiology__I-ORG for__I-ORG Clinicians__I-ORG accredited__O CPD__B-ORG course,__O which__O informs__O clinicians__O of__O new__O and__O apposite__O basic__O and__O clinical__O renal__O research.__O
In__O 2012__O Peppiatt-Wildman__O and__O Wildman__B-PER began__O working__O with__O nephrologists__O at__O Kent__B-ORG and__O Canterbury__B-LOC Hospital__I-LOC to__O address__O nephrotoxic__O side-effects__O associated__O with__O immunosuppressant__O medication__O commonly__O prescribed__O to__O renal__O transplant__O patients.__O
This__O work__O has__O resulted__O in__O an__O internal__O review__O of__O combination__O drug__O therapies__O and__O funding__O from__O Kidney__B-ORG Research__I-ORG UK.__I-ORG
Additionally,__O research__O into__O the__O chronic__O recalcitrant__O UTIs__O associated__O with__O renal__O transplant__O patients__O (using__O advanced__O urinalysis__O imaging),__O has__O instigated__O a__O local__O trial__O of__O a__O series__O of__O `bedside'__O tests,__O using__O standard__O microscopy,__O to__O help__O identify__O patients__O likely__O to__O present__O with__O recurrent__O UTIs.__B-ORG
This__O work__O has__O also__O resulted__O in__O funding__O from__O Kidney__B-ORG Research__I-ORG UK__I-ORG to__O implement__O a__O longitudinal,__O comparative,__O observational__O study.__O
Nephrologists__O at__O Kent__B-LOC and__O Canterbury__B-LOC Hospital__I-LOC began__O developing__O new__O diagnostics__O for__O recurrent__O UTIs__B-ORG in__O renal__O transplant__O patients,__O involving__O simple__O imaging,__O and__O have__O altered__O clinical__O practice__O as__O a__O result__O of__O this__O research__O collaboration__O (5.5).__O
Also__O in__O 2012,__O Peppiatt-Wildman__O and__O Wildman__B-LOC began__O investigating__O the__O aetiology__O of__O OAB__B-ORG using__O advanced__O imaging__O methodologies,__O in__O collaboration__O with__O clinicians__O at__O Medway__B-LOC NHS__I-LOC Trust.__I-LOC
The__O research__O collaboration__O focuses__O on__O the__O aetiology__O of__O OAB,__B-ORG a__O comprehensive__O search__O for__O biomarkers,__O and__O developing__O better__O `bedside'__O tests,__O of__O which__O the__O most__O promising__O involve__O simple__O imaging.__O
As__O a__O direct__O result__O of__O the__O collaboration,__O a__O laboratory__O has__O now__O been__O established__O at__O Medway__B-LOC NHS__I-LOC Trust__I-LOC Outpatients__I-LOC Department.__O
This__O serves__O primarily__O as__O an__O adjunct__O to__O continence__O clinics__O providing__O rapid,__O cost-effective,__O `bedside'__O urinalysis__O (including__O imaging__O of__O fresh__O urine__O samples)__O to__O inform__O treatment__O strategies.__O
In__O a__O short__O period__O of__O time__O this__O research__O collaboration__O has__O altered__O clinical__O practice__O (5.6).__O
Thus__O the__O impact__O of__O this__O research__O in__O clinical__O practice__O is__O the__O identification__O of__O a__O broader__O range__O of__O superior__O diagnostics__O that__O provides__O clinicians__O with__O the__O enhanced__O capacity__O to__O improve__O the__O health__O outcomes__O of__O their__O patients.__O
